Hepatitis E virus (HEV) is an important cause of hepatitis among young Egyptian adults with high seroprevalence rates seen in both rural areas of the Nile Delta and in suburban Cairo. Because natural antibodies to HEV have been detected in animals and zoonotic transmission is postulated, we surveyed
Hepatitis B virus infection in upper and lower Egypt
β Scribed by Mohamed M. Sherif; Badawy A. S. Abou-Aita; Mohamed H. Abou-Elew; Ahmed O. M. M. El-Kafrawi
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 345 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
The relative prevalence of hepatitis B surface antigen (HBsAg), anti-HBs, and anti-hepatitis B virus core antigen (HBc), as markers of hepatitis B virus infection, among 1,866 apparently healthy residents of two Egyptian provinces representing Upper and Lower Egypt populations was determined using solid-phase radioimmunoassay (SPRIA).
The prevalence rate of HBsAg in the Egyptian population was moderately high (10.1 %); it was higher in the Upper Egypt (11.7%) than the Lower Egypt (8.0%) population and more frequent in young adults-especially those of Upper Egyptand males than females in both populations. The prevalence of anti-HBs gradually increased with age; it was higher in the Lower Egypt (51.1 %) than the Upper Egypt (41.7%) population, and it was higher in females than males. A remarkably high infection rate, as shown by the prevalence of anti-HBc, was found in both populations (88.0%), with minor variations depending on age, sex, and geographic area.
π SIMILAR VOLUMES
In the present study we have investigated 53 patients with a spectrum of acute and chronic hepatitis B virus (HBV) infection for the presence of leucocyte HBV-DNA with the aid of molecular techniques. HBV-DNA was detected in peripheral blood mononuclear cells of 31 of 45 (69%) of chronic HBsAg carri
## Abstract Occult HBV infection is a wellβrecognised clinical entity characterised by the detection of HBVβDNA in serum and/or in liver in the absence of detectable hepatitis B surface antigen (HBsAg). Occult HBV infection has been described not only in patients who have resolved an acute or chron
In a previous study a partial inhibition of viral replication was observed in HBeAg-positive patients after acyclovir (ACV) treatment. To assess those results and to evaluate different treatment regimens, a randomized controlled trial with ACV given at 45 mg/kg/day by continuous infusion (in 5 pati
to be controlled for in comparing immunoprophylactic approaches. At present, DNA polymerase activity or HBV DNA is useful for estimating the level of exposure. In an editorial in this issue, Dr. Dienstag pointed out difficulties in comparing the results of two immunoprophylactic regimens conducted a